Serum sRAGE, sRANKL and osteoprotegerin in subgroups of rheumatoid arthritis patients: biomarkers associated with iron and disease status

Figures & data

Table 1. Demographic and clinical characteristics of the study groups.

Characteristics	CRP ≤8, n = 79	CRP >8, n = 35
Mean age, years	57.3 ± 10.0	58.9 ± 10.5
Sex (M/F)	12/67	4/31
DAS28	5.39 ± 1.05	6.36 ± 1.14
RF, U/mL	45 (18–142)	117 (20–362)
AntiCCP antibodies, U/mL	103 (46–206)	226 (137–783)

Note: Data are presented as mean values ± SD or median values (25^th-75^th percentile).

Figure 1. Comparison of sRAGE (A), sRANKL (B) and OPG (C) in subgroups of RA patients according to the level of CRP (CRP ≤ 8 and CRP > 8).

Table 2. Correlations of sRAGE in subgroups of RA patients according to the level of CRP (CRP ≤ 8 and CRP > 8).

Parameters	r	p	r		p
	CRP ≤8, n = 79		CRP >8, n = 35
sRAGE/sTfR	0.435	<0.0001*	0.451	0.007*
sRAGE/Prohepcidin	0.232	0.040*	0.241	NS
sRAGE/sRANKL	0.636	<0.0001*	0.637	<0.0001*
sRAGE/RF	0.363	0.002*	0.171	NS
sRAGE/AntiCCP antibodies	0.429	0.003*	0.277	NS

*statistical significance; NS, non-significant.

Table 3. Correlations of sRANKL in subgroups of RA patients according to the level of CRP (CRP ≤ 8 and CRP >8).

Parameters	r	p	r		p
	CRP ≤8, n = 79		CRP >8, n = 35
sRANKL/sRAGE	0.636	<0.0001*	0.637	<0.0001*
sRANKL/sTfR	0.513	<0.0001*	0.786	<0.0001*
sRANKL/CRP	0.223	0.048*	−0.089	NS
sRANKL/DAS28	0.269	0.016*	−0.017	NS
sRANKL/RF	0.390	0.001*	0.422	0.013*
sRANKL/AntiCCP antibodies	0.445	0.002*	0.247	NS

*statistical significance; NS, non-significant.

Table 4. Correlations of OPG in subgroups of RA patients according to the level of CRP (CRP ≤ 8 and CRP > 8).

Parameters	r	p	r		p
	CRP ≤8, n = 79		CRP >8, n = 35
OPG/Ferritin	0.320	0.004*	0.058	NS

*statistical significance; NS, non-significant.

Data availability statement

The data that support the findings of this study are available on request from the corresponding author, GD. The data are not publicly available due to their containing information that could compromise the privacy of research participants.